Antios Therapeutics Overview

  • Founded
  • 2018
Founded
  • Status
  • Private
  • Employees
  • 11
Employees
  • Latest Deal Type
  • Series A
  • Latest Deal Amount
  • $4.4M
Latest Deal Amount
  • Investors
  • 8

Antios Therapeutics General Information

Description

Developer of innovative therapies designed to focus on treating and curing viral diseases. The company's platform focuses on the development of its lead oral drug candidate for potentially curative treatment of HBV infections and novel antiviral therapies that target the liver by following one pill, the once-a-day combination regimen, enabling patients to combat viral diseases.

Contact Information

Website
www.antiostherapeutics.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 575 Pharr Road North East
  • Suite 12260
  • Atlanta, GA 30355
  • United States
+1 (212) 000-0000

Antios Therapeutics Timeline

201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Antios Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series A) 17-Aug-2020 $4.4M 000.00 000.00 Completed Generating Revenue
1. Early Stage VC (Series A) 27-Nov-2018 0000 0000 0000 Completed Generating Revenue
To view Antios Therapeutics’s complete valuation and funding history, request access »

Antios Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A 00,000,000 00.000000 00 00.0 00.0 00 00.0 00.000
To view Antios Therapeutics’s complete cap table history, request access »

Antios Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of innovative therapies designed to focus on treating and curing viral diseases. The company's platform focuse
Drug Discovery
Atlanta, GA
11 As of 2021
000.00
00.00 0000-00-00
00000000000 000.00

0000000

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatu
0000 000000000
Warminster, PA
00 As of 0000
00000
000000 - 000 00000

000000 0

sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis no
0000000000000
Edison, NJ
00 As of 0000
000.00
00000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Antios Therapeutics Competitors (3)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Arbutus Biopharma Corporate Backed or Acquired Warminster, PA 00 00000 000000 - 000 00000
000000 00000000000 Corporation Edison, NJ 00 000.00 00000000 000.00
0000000 0000000000 Formerly VC-backed Cambridge, MA 000 00000 000000000 00000
You’re viewing 3 of 3 competitors. Get the full list »

Antios Therapeutics Executive Team (5)

Name Title Board Seat Contact Info
Tamra Adams Chief Financial Officer
Idean Marvasty Co-Founder & Senior Vice President of Finance and Strategy
Abel De La Rosa Ph.D Co-Founder, Chairman of the Board of Directors & Advisor
Gregory Mayes JD Chief Executive Officer, Director, President & Board Member
Douglas Mayers MD Co-Founder & Chief Medical Officer
To view Antios Therapeutics’s complete executive team members history, request access »

Antios Therapeutics Board Members (6)

Name Representing Role Since
Abel De La Rosa Ph.D Antios Therapeutics Co-Founder, Chairman of the Board of Directors & Advisor 000 0000
Benjamin Rovinski Ph.D Lumira Ventures Board Member 000 0000
Henry Chen JD Delos Capital Partners Board Member 000 0000
Nicole Vitullo Domain Associates Board Member 000 0000
Patrick Higgins Self Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »

Antios Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Antios Therapeutics Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
CAM Capital Asset Manager Minority 000 0000 000000 0
Delos Capital Partners Venture Capital Minority 000 0000 000000 0
Domain Associates Venture Capital Minority 000 0000 000000 0
Fonds de solidarité FTQ PE/Buyout Minority 000 0000 000000 0
GRA Venture Fund Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »

Ready to get started?

Request a free trial